Steffen Thomas Biography and Net Worth

Director of Anavex Life Sciences

Steffen Thomas, PhD, a director of Anavex®, has over 15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.

What is Steffen Thomas' net worth?: The estimated net worth of Steffen Thomas is at least $47,100.00 as of May 15th, 2024. Dr. Thomas owns 5,000 shares of Anavex Life Sciences stock worth more than $47,100 as of April 26th. This net worth evaluation does not reflect any other assets that Dr. Thomas may own. Learn More about Steffen Thomas' net worth.
How do I contact Steffen Thomas?: The corporate mailing address for Dr. Thomas and other Anavex Life Sciences executives is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. Anavex Life Sciences can also be reached via phone at (844) 689-3939 and via email at ir@anavex.com. Learn More on Steffen Thomas' contact information.
Has Steffen Thomas been buying or selling shares of Anavex Life Sciences?: Steffen Thomas has not been actively trading shares of Anavex Life Sciences over the course of the past ninety days. Most recently, on Wednesday, May 15th, Steffen Thomas bought 5,000 shares of Anavex Life Sciences stock. The stock was acquired at an average cost of $4.52 per share, with a total value of $22,600.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company's stock, valued at $22,600. Learn More on Steffen Thomas' trading history.
Who are Anavex Life Sciences' active insiders?: Anavex Life Sciences' insider roster includes Sandra Boenisch (Treasurer), Peter Donhauser (Director), Elliot Favus (Director), Elliot Favus (Director), Christopher Missling (CEO), and Steffen Thomas (Director). Learn More on Anavex Life Sciences' active insiders.
Are insiders buying or selling shares of Anavex Life Sciences?: In the last twelve months, Anavex Life Sciences insiders bought shares 2 times. They purchased a total of 7,835 shares worth more than $32,919.40. The most recent insider tranaction occured on June, 14th when Director Peter D.O. Donhauser bought 2,835 shares worth more than $10,319.40. Insiders at Anavex Life Sciences own 11.0% of the company. Learn More about insider trades at Anavex Life Sciences.
Information on this page was last updated on 6/14/2024.

Steffen Thomas Insider Trading History at Anavex Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/15/2024	Buy	5,000	$4.52	$22,600.00	5,000

Steffen Thomas Buying and Selling Activity at Anavex Life Sciences

Anavex Life Sciences Company Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Today's Range

Now: $9.42

$9.31

$9.66

50 Day Range

MA: $8.79

$7.60

$9.93

2 Week Range

Now: $9.42

$3.37

$14.44

Volume

308,122 shs

Average Volume

1,232,386 shs

Market Capitalization

$801.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8